Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Part of paid clinical trials in Rockville, Maryland.
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Study ID
- NCT07033585
- Phase
- PHASE2/PHASE3
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 24 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes — DRUGFarxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
- China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes — DRUGChina Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription Treat type 2 diabetes patients with controlled cancers
Study Details
Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers
Key Dates
- Start date
- Jun 15, 2025
- Status verified
- Jul 2025
- Primary completion
- Oct 18, 2026
- Completion
- Nov 28, 2026
Study Design
- Enrollment
- 600 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Farxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral MixFarxiga® (dapagliflozin) 10 mg, Onglyza® (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription
- Experimental: China Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral MixChina Import (dapagliflozin) 10 mg, China Import (saxagliptin) 5 mg, Metformin 500 mg, Oral Mix Prescription
Primary Outcome Measure
Detect Hemoglobin A1c (HbA1c) [ Time Frame: Duration up to 90 days ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701 | Rockville | Maryland | 20853 | - |
Find similar trials in Rockville, MD
By condition
By specialty
Related Studies
- ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2Recruiting · Johns Hopkins University · Baltimore, Maryland
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II DiabetesRecruiting · Endogenex, Inc. · Birmingham, Alabama
- Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort StudyRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Washington D.C., District of Columbia
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)PHASE3 · Recruiting · Eli Lilly and Company · Tucson, Arizona